pain therapeutics inc (PTIE) Key Developments
Pain Therapeutics Announces Positive Results from Drug Abuse Study
May 27 15
Pain Therapeutics Inc. announced positive results from an FDA Category 3 Human Abuse Potential Study with REMOXY extended-release capsules CII, which is designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p < 0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.
Pain Therapeutics Inc. - Special Call
May 12 15
To discuss progress across its portfolio of drug candidates and to respond to questions
Pain Therapeutics Inc. Announces Unaudited Earnings Results for the First Quarter Ended March 31, 2015
May 7 15
Pain Therapeutics Inc. announced unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $2,595,000 against $3,464,000 a year ago. Interest income was $12,000 against $14,000 a year ago. Net loss was $2,583,000 or $0.06 basic and diluted per share against $3,450,000 or $0.08 basic and diluted per share a year ago.
Pain Therapeutics Announces Appointment of Michael Marsman as Senior Vice President, Regulatory Affairs
Apr 23 15
Pain Therapeutics Inc. announced the appointment of Michael Marsman, Pharm.D., as Senior Vice President, Regulatory Affairs. Dr. Marsman will be responsible for developing and implementing regulatory strategies to gain drug approvals. He previously led regulatory affairs at Pain Therapeutics for nearly a decade before leaving in 2012 amid a corporate reorganization. Dr. Marsman most recently served as V.P. Regulatory Affairs at Impax Laboratories.
Pain Therapeutics Inc., Annual General Meeting, May 14, 2015
Apr 7 15
Pain Therapeutics Inc., Annual General Meeting, May 14, 2015., at 10:00 Central Standard Time. Location: 7801 N Capital of Texas Highway. Agenda: To elect Remi Barbier, Sanford R. Robertson and Patrick J. Scannon, M.D., Ph.D. as Class III Directors to serve for three-year terms and until their successors are duly elected and qualified; to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the company for the fiscal year ending December 31, 2015; to approve, by a non-binding advisory vote, the 2014 executive compensation for the company’s executive officers; and to transact such other business as may properly be brought before the meeting and any adjournment(s) thereof.